AmplifyBio, a leading preclinical CRO and R&D outsourcing partner is announcing the opening of a new business unit to further expand their reach into the manufacturing of next-generation therapies that include cell, gene, mRNA, and other advanced modalities.
Read HereAn outsourced R&D solution for benchmarking next-generation therapeutics
A preclinical CRO built for the future on a decades-long foundation of expertise and experience
A manufacturing partnership for multiple modalities, offered in flexible contract staffing models to fit varied requirements